As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Sunmo succeeds in a setting very similar to Starglo's.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
